Cagrilintide
Also known as: NN9838, long-acting amylin analogue
Quick summary
Cagrilintide is a lipidated, long-acting analogue of amylin, the satiety hormone released by the pancreas alongside insulin. Research focus: amylin receptor agonism, appetite and satiety signaling and body-weight endpoints in clinical trials. This page leads with SRP's low-and-slow starting dose.
Overview
Cagrilintide is a lipidated, long-acting analogue of amylin, the satiety hormone released by the pancreas alongside insulin. Its long half-life supports once-weekly dosing in trials. It is studied both alone and paired with GLP-1 agonists.
Looking for research material? Simple Research Peptides lists Cagrilintide (10 mg Vial) for laboratory research use.
Mechanism
A long-acting amylin analog that activates both amylin receptors and calcitonin receptors. It acts on satiety centers in the brainstem, complementing GLP-1 agonists.
Research areas
- amylin receptor agonism
- appetite and satiety signaling
- body-weight endpoints in clinical trials
Storage & reconstitution
Supplied as a lyophilized powder; keep sealed, dry and away from light, ideally frozen or refrigerated for long-term holding. Laboratories typically reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, then hold the solution refrigerated (2–8 °C) and use it within the window set by their own stability protocol.
Recommended starting dose (low and slow)
| Starting dose | Start at 0.25 mg once weekly; quote trial ranges that begin at 0.3-0.6 mg. |
|---|---|
| Frequency | Reported schedules: 1x weekly; 0.6–4.5mg weekly; Weekly. |
| Reconstitution | Examples: 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL; 10 mg vial + 2 mL water = 5 mg/mL; 5mg vial + 2mL diluent (as listed). storage note: Reconstituted: refrigerate; used within 4–8 weeks. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Reports conflict: stop at 2.4 mg weekly, while go to 4.5 mg weekly. The phase 2 trial (Lancet 2021, tested 0.3, 0.6, 1.2, 2.4 and 4.5 mg weekly arms, so 4.5 mg is the highest studied. |
|---|---|
| Step-up schedules reported | Ladder steps every 4 weeks: 0.25, 0.5, 1.0, 1.7 mg, then 2.4 mg weekly from week 17. A common standalone ladder, not taken from a trial; the phase 2 trial tested fixed-dose arms instead (see maximum). |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: About 7 to 8 days.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; fasting glucose, HbA1c and lipid panel; lipase where GLP-1 or amylin-pathway compounds are involved.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Cagrilintide studied for?
In research it is studied for amylin receptor agonism, appetite and satiety signaling and body-weight endpoints in clinical trials. A long-acting amylin analog that activates both amylin receptors and calcitonin receptors.
How is Cagrilintide given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026